Caribou Biosciences (CRBU) Cash from Financing Activities (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Cash from Financing Activities data on file, last reported at $2.7 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 476.07% year-over-year to $2.7 million in Q1 2026; TTM through Mar 2026 was $7.0 million, a 49.76% increase from a year earlier, with the FY2025 full-year figure at $4.8 million, down 71.17% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $2.7 million, down from $4.1 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for CRBU reached as high as $135.1 million in Q3 2023 and fell as low as -$43000.0 in Q4 2023.
• Historically, Cash from Financing Activities has averaged $10.6 million across 5 years, with a median of $654000.0 in 2022.
• On a YoY basis, Cash from Financing Activities climbed as much as 20561.77% in 2023 and fell as far as 133.86% in 2023.
• Year by year, Cash from Financing Activities stood at $127000.0 in 2022, then sank by 133.86% to -$43000.0 in 2023, then surged by 9083.72% to $3.9 million in 2024, then grew by 5.36% to $4.1 million in 2025, then sank by 33.76% to $2.7 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $2.7 million in Q1 2026, $4.1 million in Q4 2025, and $277000.0 in Q3 2025.